Barclays Sees 40% Upside In Versartis Over Next Year
March 09, 2017 at 09:14 AM EST
Barclays’ Geoff Meacham expects Versartis Inc (NASDAQ: VSAR) to report “pivotal phase 3 data of somavaratan in pediatric ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.